By Izzy Wood (Drug Target Review)2023-07-05T12:03:58
Using a newly developed algorithm and a validation study, US researchers find that cancer hijacks a class of enzyme mutations to fuel tumorigenesis.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-26T13:58:00Z
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2024-01-10T08:56:17
Sponsored by Leica Microsystems
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2024-02-01T12:06:43
Sponsored by Leica Microsystems
Site powered by Webvision Cloud